← All trials
NCT03401398
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 2, 2019
- Primary completion
- Jan 31, 2023
- Completion date
- Apr 30, 2023
- First posted
- —
- Last posted
- —
- Enrollment
- 1032
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- University of WashingtonLead sponsor
- Harvard UniversityOverall official - principal investigator
- National Institutes of Health (NIH)Collaborator
- University of OttawaOverall official - principal investigator
- University of OttawaCollaborator
- University of CincinnatiOverall official - principal investigator
- Canadian Institutes of Health Research (CIHR)Collaborator
- Canadian Critical Care Trials GroupCollaborator
- University of WashingtonSponsor investigator
- University of WashingtonOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.